{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:36:02Z","timestamp":1773725762624,"version":"3.50.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"DOI":"10.1093\/oncolo\/oyaf216","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T18:52:47Z","timestamp":1752778367000},"source":"Crossref","is-referenced-by-count":1,"title":["Contextualizing results of randomized trials in smoldering myeloma"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-783X","authenticated-orcid":false,"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"first","affiliation":[{"name":"Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT 84106,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron M","family":"Goodman","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, University of California San Diego , CA 92037,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-3003","authenticated-orcid":false,"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Division of Hematology, Columbia University Irving Cancer Center , New York City, NY 10027,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"2025091815415518400_oyaf216-B1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","article-title":"Prevalence of smoldering multiple myeloma based on nationwide screening","volume":"29","author":"Thorsteinsd\u00f3ttir","year":"2023","journal-title":"Nat Med"},{"key":"2025091815415518400_oyaf216-B2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025091815415518400_oyaf216-B3","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025091815415518400_oyaf216-B4","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"key":"2025091815415518400_oyaf216-B5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","article-title":"Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized, open-label study","volume":"174","author":"Mateos","year":"2022","journal-title":"Eur J Cancer"},{"key":"2025091815415518400_oyaf216-B6","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","article-title":"Daratumumab or active monitoring for high-risk smoldering multiple myeloma","volume":"392","author":"Dimopoulos","year":"2025","journal-title":"N Engl J Med"},{"key":"2025091815415518400_oyaf216-B7","doi-asserted-by":"crossref","first-page":"101910","DOI":"10.1016\/j.eclinm.2023.101910","article-title":"SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of \u2018biomarker-defined early multiple myeloma\u2019-a systematic review with meta-analysis","volume":"58","author":"Ludwig","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025091815415518400_oyaf216-B8","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2025016083","article-title":"Patterns of progression among 427 smoldering myeloma patients diagnosed after 2014: importance of monitoring","author":"Kastritis","year":"2025","journal-title":"Blood Adv"},{"key":"2025091815415518400_oyaf216-B9","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41408-024-01159-8","article-title":"Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma","volume":"14","author":"Werly","year":"2024","journal-title":"Blood Cancer J"},{"key":"2025091815415518400_oyaf216-B10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-024-00980-5","article-title":"Mode of progression in smoldering multiple myeloma: a study of 406 patients","volume":"14","author":"Abdallah","year":"2024","journal-title":"Blood Cancer J"},{"key":"2025091815415518400_oyaf216-B11","author":"FDA Advisory Committee Meeting","year":"2025"},{"key":"2025091815415518400_oyaf216-B12","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1182\/blood-2024-203858","article-title":"Risk and patterns of progression among smoldering myeloma patients after the implementation of new criteria and modern imaging","volume":"144","author":"Kastritis","year":"2024","journal-title":"Blood"},{"key":"2025091815415518400_oyaf216-B13","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1002\/hem3.61","article-title":"Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma","volume":"8","author":"Mellgard","year":"2024","journal-title":"Hemasphere"},{"key":"2025091815415518400_oyaf216-B14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41408-020-00360-9","article-title":"The role of low dose whole body CT in the detection of progression of patients with smoldering multiple myeloma","volume":"10","author":"Gavriatopoulou","year":"2020","journal-title":"Blood Cancer J"},{"key":"2025091815415518400_oyaf216-B15","doi-asserted-by":"crossref","first-page":"e218084","DOI":"10.1001\/jamanetworkopen.2021.8084","article-title":"Reporting of postprotocol therapies and attrition in multiple myeloma randomized clinical trials: a systematic review","volume":"4","author":"Mohyuddin","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025091815415518400_oyaf216-B16","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"2025091815415518400_oyaf216-B17","doi-asserted-by":"crossref","first-page":"e210048","DOI":"10.1148\/rycan.2021210048","article-title":"Prospective evaluation of Whole-Body MRI versus FDG PET\/CT for lesion detection in participants with myeloma","volume":"3","author":"Messiou","year":"2021","journal-title":"Radiol Imaging Cancer"},{"key":"2025091815415518400_oyaf216-B18","first-page":"479","article-title":"Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities","volume":"5","author":"Sachpekidis","year":"2015","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"2025091815415518400_oyaf216-B19","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2214\/AJR.07.2635","article-title":"Whole-body MRI versus whole-body MDCT for staging of multiple myeloma","volume":"190","author":"Baur-Melnyk","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"2025091815415518400_oyaf216-B20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1148\/radiol.2522081756","article-title":"Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging","volume":"252","author":"B\u00e4uerle","year":"2009","journal-title":"Radiology"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf216\/63790798\/oyaf216.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf216\/63790798\/oyaf216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf216\/63790798\/oyaf216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T19:42:05Z","timestamp":1758224525000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf216\/8205680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf216","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,17]]},"article-number":"oyaf216"}}